99mTc-labeled PSMA inhibitor: Biokinetics and Radiation Dosimetry in Healthy Subjects and Imaging of Prostate Cancer Tumors in Patients

The prostate-specific membrane antigen (PSMA) is expressed in epithelial cells of the prostate and highly overexpressed in 95% of advanced prostate cancers. The aim of this study was to estimate the biokinetics and dosimetry of 99mTc-EDDA/HYNIC-iPSMA (99mTc-labeled PSMA inhibitor) in eight healthy subjects and evaluate its usefulness as a tumor-imaging agent in eight prostate cancer patients.

Source: Nuclear Medicine and Biology - May 25, 2017 Category: Nuclear Medicine Authors: Clara Santos-Cuevas, Jenny Davanzo, Guillermina Ferro-Flores, Francisco O. Garc ía-Pérez, Blanca Ocampo-García, Eleazar Ignacio-Alvarez, Edgar Gómez-Argumosa, Martha Pedraza-López Source Type: research